Result of Subscription
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as imported into the laws of England and Wales by virtue of the European Union (Withdrawal) Act 2018 (as amended) and certain other enacting measures ("UK MAR"). With the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
24 September 2026
MicroSalt Plc
("MicroSalt" or the "Company")
Result of Subscription
MicroSalt (AIM: SALT), a leading manufacturer of full-flavour natural salt containing approximately 50% less sodium, is pleased to announce that the primary component of the Fundraising, the Subscription (as announced on 16 September 2026), was significantly over-subscribed and has now closed.
The Subscription has conditionally raised gross proceeds of approximately £1.3 million / US$1.7 million (before expenses) through the issuance of 9,213,858 Subscription Shares at 14 pence per Ordinary Share (the “Issue Price”).
On issue, each Fundraising Share (comprising the Subscription Shares, the proposed Director Subscription Shares and Retail Offer Shares) will have one warrant attached (a “Fundraising Warrant”), conditionally entitling the holder to subscribe for one new Ordinary Share in the capital of the Company (a “Warrant Share”). The allotment and issue of the Warrant Shares is conditional upon, among other things, the Company having sufficient shareholder authorities available at the time of exercise of the Fundraising Warrant or obtaining such shareholder approvals if insufficient authorities are available. The Fundraising Warrants will be exercisable for a period of three years following Admission at an exercise price of 14 pence per Warrant Share. The Fundraising Warrants will not be admitted to trading on AIM.
In addition to the Subscription, the Director Subscription is expected to raise approximately £140,000/ US$180,000, resulting in expected total gross proceeds of £1.4 million.
The Company is also providing existing Shareholders who have not participated in the Subscription or the proposed Director Subscription with the opportunity to subscribe for up to 714,285 Retail Offer Shares at the Issue Price, to raise up to £100,000 (before expenses), pursuant to a separate retail offer to be conducted via the Bookbuild Platform. Neither the Subscription nor the Director Subscription is conditional on the Retail Offer proceeding or on any minimum take-up under the Retail Offer. The Retail Offer is expected to open at 8.00 a.m. on 25 September 2026 and close at 5.00 p.m. on 29 September 2026. Further details of the Retail Offer will be set out in a separate announcement to be released shortly after this announcement.
As announced on 10 September 2026, the Ordinary Shares entered a Capital Access Window at 7.30 a.m. on that date. The Capital Access Window will cease at 2.00 p.m. on 24 September 2026, following which trading in the Ordinary Shares will resume. Admission of the 11,077,468 Conversion Shares to trading on AIM is expected to become effective, and dealings in the Conversion Shares are expected to commence, at 8.00 a.m. on 25 September 2026.
Expected timetable of the Fundraise
The expected timetable of the Fundraise has been amended as follows:
|
|
2026 |
|
Result of the Subscription announced |
2:00 p.m. on 24 September |
|
Capital Access Window closed |
2:00 p.m. on 24 September |
|
Launch of Retail Offer |
8.00 a.m. on 25 September |
|
Admission and commencement of dealings in the Conversion Shares |
8:00 a.m. on 25 September |
|
Interim Results announced |
7:00 a.m. on 29 September |
|
Announcement of any Director Subscriptions |
By 3:00 p.m. on 29 September |
|
Latest time and date for receipt of online proxy votes or completed Forms of Proxy |
11:00 a.m. on 30 September |
|
General Meeting |
11:00 a.m. on 2 October |
|
Results of the General Meeting announced |
2 October |
|
Admission and commencement of dealings in the Fundraising Shares on AIM |
8:00 a.m. on 5 October |
|
CREST accounts expected to be credited with Fundraising Shares and Fundraising Warrants in uncertificated form (uncertificated holders only) |
5 October |
|
Expected dispatch of definitive share certificates in respect of Fundraising Shares and certificates in respect of Fundraising Warrants to be issued in certificated form (certificated holders only) |
Within 10 Business Days of Admission |
Notes:
- Capitalised terms used but not defined in this announcement have the meanings given to them in the Company's announcement released at 1:30pm on 16 September 2026.
- Unless otherwise specified, references in this Announcement to time refer to British Summer Time.
For more information, please contact:
|
MicroSalt plc |
Via Gracechurch Group |
|
Rick Guiney, CEO Gary Urmston, Interim CFO |
|
|
|
|
|
Zeus (Nominated adviser and broker) David Foreman / Ed Beddows (Investment Banking) Nick Searle (Head of Equity Capital Markets) |
+44 (0)20 3829 5000 |
|
|
|
|
Gracechurch Group (Financial PR) |
+44 (0)20 4582 3500 |
|
Heather Armstrong, Alexis Gore, Rebecca Scott |
|
About MicroSalt
MicroSalt is disrupting the global salt market with its patented, full-flavour, low-sodium salt designed for both food manufacturers and consumers. Using proprietary micron-sized particles, MicroSalt delivers the same salty taste as traditional salt with approximately 50% less sodium, offering a scalable solution to one of the world's most pressing health challenges.
Excess sodium consumption is a leading contributor to cardiovascular disease, the world's number one cause of death. The World Health Organisation has targeted a 30% reduction in global sodium intake by 2025, a shift projected to save seven million lives by 2030. The economic case is equally compelling: in the UK alone, cardiovascular disease costs £19 billion annually, and reducing average daily salt intake by just one gram could save over 4,000 lives and £288 million each year.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE